Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24849997 | 0.90 | TRPV1 (0.64) | ABL1TRPV1MEN1POLBKMT2A | |
| SCHEMBL24849958 | 0.81 | ABL1 (0.52) | ABL1TRPV1ALDH1A1 | |
| SCHEMBL24850836 | 0.81 | ABL1 (0.52) | ABL1ALDH1A1 | |
| SCHEMBL28833677 | 0.80 | TRPV1 (0.61) | ABL1TRPV1MEN1POLBKMT2A | |
| SCHEMBL24850253 | 0.79 | ABL1 (0.50) | ABL1 | |
| SCHEMBL29832702 | 0.78 | ABL1 (0.62) | ABL1TRPV1MEN1POLBKMT2A | |
| SCHEMBL24850309 | 0.78 | ABL1 (0.52) | ABL1TRPV1ALDH1A1 | |
| SCHEMBL28932363 | 0.76 | TRPV1 (0.50) | ABL1TRPV1MEN1KMT2AALDH1A1 | |
| SCHEMBL23091741 | 0.75 | TRPV1 (0.53) | ABL1TRPV1MEN1KMT2AALDH1A1 | |
| SCHEMBL23091739 | 0.75 | ABL1 (0.49) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | BenevolentAl Bio Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | BenevolentAl Bio Limited (GB) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | ABL1 2/4885TRPV1 1085/4885MEN1 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.